Results 211 to 220 of about 124,601 (306)

When Small Cells Matter: Diagnosing Bladder Small Cell Carcinoma on Urine Cytology

open access: yesCytopathology, EarlyView.
Small cell carcinoma of the bladder is rare, aggressive and diagnostically challenging on urine cytology. We report a case detected in urine and confirmed by cell block immunohistochemistry, highlighting the importance of careful assessment and limitations of the Paris System.
Haley Corbin   +3 more
wiley   +1 more source

What Are Computer‐Assisted Methods Achieving in Fine‐Needle Aspiration Cytology of the Pancreas? A Systematic Review and Meta‐Analysis

open access: yesCytopathology, EarlyView.
This meta‐analysis demonstrates high diagnostic accuracy of computer‐assisted methods in pancreatic EUS‐FNA cytology (AUC 0.92–0.96) and supports an integrated, cytopathologist‐led workflow in which artificial intelligence functions as an adjunct to diagnostic interpretation and on‐site evaluation (ROSE). Created in BioRender. Mohamed Mirzan, A. (2026)
Al‐Amaan Mohamed Mirzan, Roberto Dina
wiley   +1 more source

Retinal vasculitis as a presenting sign of Epstein-Barr virus positive diffuse large B-cell lymphoma: a case report. [PDF]

open access: yesBMC Ophthalmol
Yavari N   +11 more
europepmc   +1 more source

S3 guideline diagnostics and therapy in alopecia areata – Part 2: Therapy, psychosocial and cosmetic support

open access: yesJDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary This second part of the S3 guideline on the diagnosis and treatment of alopecia areata (AA), presents key recommendations on topical and systemic therapy, quality of life and support services. The first part of the guideline, published separately, covers the definition and content of epidemiology and diagnosis as well as comorbidities, risk and
Ulrike Blume‐Peytavi   +13 more
wiley   +1 more source

The different face of skin‐rash induced by brentuximab vedotin

open access: yesJDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background: Brentuximab vedotin (BV) is a targeted therapy for CD30‐expressing lymphomas, including Hodgkin lymphoma (HL) and cutaneous T‐cell lymphoma (CTCL). While peripheral neuropathy is the most common adverse event, BV‐induced skin rashes are less frequent and not well characterized.
Alessandro Pileri   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy